Ярослав Шпарик
Ярослав Шпарик
Lviv cancer center
Немає підтвердженої електронної адреси
Назва
Посилання
Посилання
Рік
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
13682015
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer
MER O'Brien, TE Ciuleanu, H Tsekov, Y Shparyk, B Cucevia, G Juhasz, ...
Journal of Clinical Oncology 24 (34), 5441-5447, 2006
5442006
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ...
The Lancet 388 (10063), 2997-3005, 2016
3082016
Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal …
JR Hecht, YJ Bang, SK Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 34 (5), 443-451, 2016
2932016
Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The …
JR Hecht, YJ Bang, S Qin, HC Chung, JM Xu, JO Park, K Jeziorski, ...
Journal of Clinical Oncology 31 (18_suppl), LBA4001-LBA4001, 2013
1962013
Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial
A Carrato, A Swieboda-Sadlej, M Staszewska-Skurczynska, R Lim, ...
Journal of Clinical Oncology 31 (10), 1341-1347, 2013
1242013
Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled …
D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, ...
European journal of cancer 70, 146-155, 2017
802017
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced …
EJ Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV ...
Breast Cancer Res Treat. 183 (2), 419-428, 0
75*
Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for …
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
Cancer Research 74 (19 Supplement), CT101-CT101, 2014
712014
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer …
HS Han, V Diéras, M Robson, M Palácová, PK Marcom, A Jager, ...
Annals of Oncology 29 (1), 154-161, 2018
672018
Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor–positive locally advanced or metastatic breast cancer
NK Ibrahim, KO Yariz, I Bondarenko, A Manikhas, V Semiglazov, ...
Clinical Cancer Research 17 (21), 6822-6830, 2011
522011
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
HS Rugo, V Diéras, KA Gelmon, RS Finn, DJ Slamon, M Martin, P Neven, ...
Annals of Oncology 29 (4), 888-894, 2018
482018
Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study
T Eisen, Y Shparyk, N Macleod, R Jones, G Wallenstein, G Temple, ...
Investigational new drugs 31 (5), 1283-1293, 2013
422013
Иммунологические механизмы естественной противоопухолевой резистентности
БТ Билынский, НА Володько, ЯВ Шпарык
Киев: Наукова думка 248, 1991
421991
Phase III, randomized, double-blind study comparing the efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab in patients treated with …
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, JH Ahn, ...
J Clin Oncol 36 (10), 968-974, 2018
412018
A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Journal of Clinical Oncology, 2016
382016
Онкологія (підручник)
БТ Білинський, ЮМ Стернюк, ЯВ Шпарик
Медицина світу, 2004
332004
A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant …
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, JH Ahn, SA Im, ...
European Journal of Cancer 93, 19-27, 2018
322018
Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel …
YH Im, P Odarchenko, D Grecea, D Komov, CV Anatoliy, S Gupta, ...
Journal of Clinical Oncology 31 (15_suppl), 629-629, 2013
312013
A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
T Eisen, AB Loembe, Y Shparyk, N MacLeod, RJ Jones, M Mazurkiewicz, ...
British journal of cancer 113 (8), 1140-1147, 2015
292015
У даний момент система не може виконати операцію. Спробуйте пізніше.
Статті 1–20